959236-96-5

Basic information

• Product Name: 8-Fluoro-2,4(1H,3H)-quinazolinedione
• Synonyms: 8-Fluoro-2,4(1H,3H)-quinazolinedione;8-Fluoroquinazoline-2,4(1H,3H)-dione
• CAS NO: 959236-96-5
• Molecular Formula: C₈H₅FN₂O₂
• Molecular Weight: 180.1359032
• Mol File: 959236-96-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 8-Fluoro-2,4(1H,3H)-quinazolinedione(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Fluoro-2,4(1H,3H)-quinazolinedione(959236-96-5)
• EPA Substance Registry System: 8-Fluoro-2,4(1H,3H)-quinazolinedione(959236-96-5)

Safety Data

• Hazardous Substances Data: 959236-96-5(Hazardous Substances Data)

Usage

General Description

8-Fluoro-2,4(1H,3H)-quinazolinedione is a chemical compound with the molecular formula C8H4FNO2. It is a quinazoline derivative, which belongs to the class of organic compounds known as quinazolinediones. 8-Fluoro-2,4(1H,3H)-quinazolinedione is also known as 8-Fluoro-1H-quinozolinedione and is used in the pharmaceutical industry as a building block for the synthesis of various other compounds. Its chemical structure and properties make it suitable for use in the development of pharmaceutical drugs and other medical applications.

Upstream product

• 590-28-3 potassium cyanate 
• 825-22-9 3-fluoroanthranilic acid 
• 57-13-6 urea 
• 124-38-9 carbon dioxide 
• 115661-37-5 2-amino-3-fluorobenzonitrile 

Downstream Products

• 959237-64-0 2,4-dichloro-8-fluoroquinazoline 
• 139996-64-8 2-chloro-8-fluoro-N-methyl-N-phenylquinazolin-4-amine 
• 1292802-72-2 2-N-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propyl)-8-fluoro-4-N-(furan-2-ylmethyl)quinazoline-2,4-diamine 
• 1356349-42-2 N-[2-({[(2S)-1-cyclopentylpropan-2-yl]amino}methyl)-4-fluorophenyl]-8-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide 
• 1356349-83-1 tert-butyl [(2S)-1-cyclopentylpropan-2-yl](5-fluoro-2-{[(8-fluoro-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)sulfonyl]amino}benzyl)carbamate 

Relevant articles and documents

Method for preparing 2,4-(1H,3H)-quinazoline diketone compound

The invention discloses a method for preparing a 2,4-(1H,3H)-quinazoline diketone compound. A 2-aminobenzonitrile compound as shown in a formula (1) and carbon dioxide are used as raw materials and react in 2-hydroxypyridine ionic liquid to obtain the 2,4-(1H,3H)-quinazoline diketone compound as shown in a formula (II), and the reaction formula is as shown in the specification. When the ionic liquid is applied to the reaction for preparing the 2,4-(1H,3H)-quinazoline diketone compound, the reaction condition is mild, the separation and purification process of the product is simple, the product yield is high, and the substrate application range is wide.

Synthesis and Characterization of Amidato Divalent Lanthanide Complexes and Their Use in Forming 2,4-Quinazolidinones from CO2 and 2-Aminobenzonitriles

Four amidato divalent lanthanide complexes, {LnLn[N(TMS)2]THF}2 [n = 1, Ln = Eu (1); n = 2, Ln = Eu (3), Yb (4); HL1 = tBuC6H4CONHC6H3(iPr)2; HL2 = C6H5CONHC6H3(iPr)2] and {L3Eu[N(TMS)2]THF}{L32Eu(THF)2} (2) [HL3 = ClC6H4CONHC6H3(iPr)2], were synthesized and extensively characterized. This is the first time that the amidato lanthanide amides 1-4 were used to catalyze the reactions of CO2 and 2-aminobenzonitriles to form quinazoline-2,4(1H,3H)-diones at atmospheric pressure. All the complexes efficiently catalyzed the transformation, with complex 3 showing the highest activity. This catalytic system gave good to excellent yields, and good functional group tolerance. Preliminary studies were conducted to investigate the reaction mechanism.

HETEROCYCLIC SULFONAMIDES AS INHIBITORS OF TRANSFER RNA SYNTHETASE FOR USE AS ANTIBACTERIAL AGENTS

The present invention provides aromatic sulphonamides as tRNA synthetase inhibitors and process for their synthesis, pharmaceutical composition and method for treatment. Compounds disclosed can be used as antibacterial agents for the treatment or prevention of conditions caused by or contributed by aerobic and anaerobic Gram-positive pathogens, more particularly against bacterium, for example Staphylococcus, Enterococci and Streptococci. Compounds disclosed are used in particular for the treatment of skin and soft tissue infection, Formula (I)